Latest News

Julie M. Vose, MD, MBA, discussed how the digital age is impacting oncology care.

This retrospective claims analysis found neutropenia carried substantial economic burden in HR+/HER2– and triple-negative mBC, with the highest neutropenia-related costs seen during sacituzumab govitecan regimens.

This review of monarchE and TRADE data demonstrates that abemaciclib dose modifications manage treatment-related adverse events without compromising efficacy in high-risk HR+, HER2− early breast cancer.

A phase 3 trial with givastomig plus nivolumab and chemotherapy in first-line HER2-negative metastatic gastric cancer is planned in Q4 2026.

This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.

Treatment with ADCs for metastatic TNBC comes with a unique set of toxicities, and know how to manage, or adjust treatment as needed is important.

This descriptive systematic review of 14 studies found diagnostic delay in PABC was common and multifactorial, driven by both patient- and provider-related factors including symptom misattribution to pregnancy.

This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.

Panelists discussed 4 trials, which focused on 3 different ADCs and how each one is being utilized in their clinical practice.

The phase 2 AMPLIFY-7P trial did not meet its primary DFS end point, though post-hoc analyses identified a benefit in R0-resected patients with mKRAS PDAC.

Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.

The FDA has accepted the BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.

Emmanuel Bachy, MD, PhD, shared data from a phase 1b study evaluating subcutaneous mosunetuzumab plus lenalidomide in untreated follicular lymphoma.

This prospective, single-arm observational trial examines whether aromatase inhibitor therapy in postmenopausal women with HR-positive breast cancer adversely affects cardiorespiratory fitness, skeletal muscle function, and immunosenescence.

This randomized multicenter pilot trial assesses feasibility of the THRIVE Wellness Program, a 6-week lifestyle intervention for young breast cancer survivors aged 40 years or younger.

Data from a phase 1/2 trial show durable disease control with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

The FDA has approved gadoquatrane for contrast-enhanced MRI to detect lesions with abnormal vascularity in the central nervous system and body.

Brentuximab vedotin plus ifosfamide, carboplatin, and etoposide conferred significantly increased toxicity vs 2 other chemotherapy-containing regimens.

Early interim data from the 3 patients with recurrent glioblastoma showed 100% local disease control and a 67% complete response rate with Alpha DaRT.

Phase 1 data support arlo-cel as a potentially effective early-line treatment option for those with relapsed/refractory multiple myeloma.

Daniel C. McFarland, DO, sat down with psycho-oncology expert Kaleena Chilcote, MD, to discuss the complexities of personality disorders in the cancer clinic.

Survey of safety-net breast cancer patients links stronger faith to greater trust in doctors, especially among Black and lower-income groups.

Explore how breast cancer stem cell plasticity, epigenetic reprogramming, and single-cell insights drive therapy resistance, revealing new targets to improve durable responses.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

Emmanuel Bachy, MD, PhD, highlighted high efficacy, durable responses, and a favorable adverse effect profile in follicular lymphoma with high tumor burden.

In BRUIN CLL-322, fixed-duration pirtobrutinib plus venetoclax/rituximab improved PFS vs venetoclax/rituximab in relapsed/refractory CLL.

Combining pirtobrutinib with venetoclax/rituximab yielded high MRD clearance among those with CLL/SLL in the phase 3 BRUIN CLL-322 trial.

In KOMET-007, ziftomenib plus 7+3 produced high responses and MRD-negativity rates in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.

The safety profile of the CAR T-cell product in the real world was consistent with that observed in the TRANSCEND MCL study.

No new safety signals were observed with the LAG-3 inhibitor-based therapy among patients with relapsed/refractory classic Hodgkin lymphoma.

Explore how newer HER2 therapies and anthracycline-sparing regimens cut breast cancer heart damage, with monitoring and cardioprotective drugs.